{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[9,2,9,3],[10,2,10,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910778895203321"]
[null,null,"Titolo",null,"Advanced therapy of prostate disease [[electronic resource] /] / [edited by] Martin I. Resnick, Ian M. Thompson"]
[null,null,"Pubbl/distr/stampa",null,"Hamilton [Ont.], : B.C. Decker"]
[{"$nulls":4},"Lewiston, NY, : Sales and distribution United States, B.C. Decker, 2000"]
[null,null,"ISBN",null,"0-585-37523-2"]
[null,null,"Descrizione fisica",null,"1 online resource (684 p.)"]
[null,null,"Disciplina",null,"616.6/5/06"]
[null,null,"Soggetti",null,"Prostate - Cancer"]
[{"$nulls":4},"Benign prostatic hyperplasia"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"Half Title Page\"\"; \"\"Title Page\"\"; \"\"Copyright page\"\"; \"\"Contributors\"\"; \"\"Preface\"\"; \"\"Dedication\"\"; \"\"Table of Contents\"\"; \"\"Chapter 1: Epidemiology of Prostate Cancer: an Overview\"\"; \"\"Chapter 2: Epidemiology of Prostate Cancer in African Americans\"\"; \"\"Chapter 3: Epidemiology of Prostate Cancer in Africa\"\"; \"\"Chapter 4: Prostate Cancer among the Chinese: Pathologic, Epidem\"\"; \"\"Chapter 5: Epidemiology of Prostate Cancer in Jamaicans\"\"; \"\"Chapter 6: Epidemiology of Prostate Cancer in Hispanic Americans\"\"; \"\"Chapter 7: Assessment of Risk of Prostate Cancer: Algorithms for\"\""]
[{"$nulls":4},"\"\"Chapter 8: Molecular Factors in the Assessment of Prostate Cancer\"\"\"\"Chapter 9: Screening for Prostate Cancer: an Overview\"\"; \"\"Chapter 10: The Optimal Diagnostic Tool: Assessment of Diagnostic\"\"; \"\"Chapter 11: Screening for Prostate Cancer: the Case for Screening\"\"; \"\"Chapter 12: Screening for Prostate Cancer: the Argument for Cauti\"\"; \"\"Chapter 13: Natural History of Localized Adenocarcinoma of the Pr\"\"; \"\"Chapter 14: Prostate Physiology and Regulation\"\"; \"\"Chapter 15: Pathobiology of Prostate Diseases: an Update\"\"; \"\"Chapter 16: Models of Prostate Cancer\"\""]
[{"$nulls":4},"\"\"Chapter 17: Diagnosis of Prostate Cancer\"\"\"\"Chapter 18: Staging of Prostate Cancer\"\"; \"\"Chapter 19: Radical Prostatectomy: Patient Preparation\"\"; \"\"Chapter 20: Stage T1a Prostate Cancer: the Case for Treatment \"\"; \"\"Chapter 21: T1b-T2NxM0: the Case for Observation \"\"; \"\"Chapter 22: Radical Retropubic Prostatectomy for Clinical Stage T1b\"\"; \"\"Chapter 23: Radical Perineal Prostatectomy \"\"; \"\"Chapter 24: Continence-Enhancing Modifications for Radical Prostat\"\"; \"\"Chapter 25: "]
[{"$nulls":4},"T1-T2NxM0: the Case for External Radiotherapy\"\"; \"\"Chapter 26: Permanent Low-Dose-Rate Interstitial Brachytherapy \"\""]
[{"$nulls":4},"\"\"Chapter 27: T1b-T2NxM0: a Case for Hormonal Therapy?\"\"\"\"Chapter 28: Role of Cryosurgery in the Treatment of Prostate Cancer\"\"; \"\"Chapter 29: Should T1c Disease Be Treated Differently from T2 Dise \"\"; \"\"Chapter 30: T3-T4NxM0: the Case for Observation\"\"; \"\"Chapter 31: T3-T4NxM0: the Case for Radiotherapy\"\"; \"\"Chapter 32: Clinical-Pathologic T3NxM0 Prostate Cancer: the Case\"\"; \"\"Chapter 33: Node-Positive Prostate Cancer: the Case for Observatio \"\"; \"\"Chapter 34: TxN+M0: the Case for Radiotherapy\"\"; \"\"Chapter 35: TxN+M0 Disease: the Case for Early Hormonal Therapy\"\""]
[{"$nulls":4},"\"\"Chapter 36: TxNxM1: the Case for Monotherapy\"\"\"\"Chapter 37: TxNxM1: the Case for Total Androgen Deprivation \"\"; \"\"Chapter 38: Is Early Hormonal Therapy Preferable?\"\"; \"\"Chapter 39: Staging Failures of Initial Therapy \"\"; \"\"Chapter 40: Management of Prostate-Specific Antigen Failure after\"\"; \"\"Chapter 41: Management of Local Failure following Treatment of Lo\"\"; \"\"Chapter 42: Secondary Hormonal Therapy\"\"; \"\"Chapter 43: Management of Hormone-Refractory Prostate Cancer:\"\"; \"\"Chapter 44: The Artificial Genitourinary Sphincter \"\""]
[{"$nulls":4},"\"\"Chapter 45: Collagen Therapy for Postprostatectomy Incontinence \"\""]